In an update to our July 25 story, Medicare Administrative Contractors (MACs) publicly announced removal of Tezspire from their Self-Administration Drug (SAD) exclusion lists. Medicare beneficiaries with severe asthma will continue to have access to Tezspire administration at their allergists’ offices.
As background, in late June, the Advocacy Council was informed of a decision that under Medicare Local Coverage Determinations (LCD), Tezspire, a treatment for severe asthma, would be moved to the SAD list and would require Medicare patients to self-administer the drug.
The Advocacy Council sent letters to the CMS, HHS and all the U.S. Medicare Administrative Contractors, opposing the movement of Tezspire to the SAD list. Fortunately, we were successful.
The Advocacy Council – ADVOCATING FOR ALLERGISTS AND THEIR PATIENTS